AVIR 241220 2.50P (AVIR241220P2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

AVIR241220P2500

Watchlist

0.03
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2
Moomoo NewsDec 5 12:31 ET · Ratings
Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges
TipRanksDec 5 12:18 ET · Ratings
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
BenzingaDec 4 15:14 ET
Express News | Atea Pharmaceuticals Inc: Global Phase 3 Program Initiation Expected Early in 2025
ReutersDec 4 08:20 ET
Express News | Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...
BenzingaDec 4 07:02 ET
Express News | Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks
ReutersDec 4 07:01 ET

Comments

102352692

Dec 4 09:00

$Atea Pharmaceuticals (AVIR.US)$ good news why drop?? surprise

Coles

Dec 4 07:08

$Atea Pharmaceuticals (AVIR.US)$ uhh hello 99% success rate

Jaguar8

Nov 15 10:01

NEWS

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment.
The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course.
Key f...

Jaguar8

May 22 08:56

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Jaguar8

Apr 29 06:04

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV trea...